• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

摩洛哥全球新冠疫情的演变以及了解壳聚糖在控制疫情中的不同治疗方法。

The evolution of the global COVID-19 epidemic in Morocco and understanding the different therapeutic approaches of chitosan in the control of the pandemic.

作者信息

Ait Hamdan Youssef, El Amerany Fatima, Desbrières Jacques, Aghrinane Abdessadek, Oudadesse Hassane, Rhazi Mohammed

机构信息

Interdisciplinary Laboratory in Bio-Resources, Environment and Materials, Higher Normal School, Department of Biology, Cadi Ayyad University, 40000 Marrakech, Morocco.

Univ Rennes, CNRS, ISCR-UMR 6226, F-35000 Rennes, France.

出版信息

Polym Bull (Berl). 2022 Nov 21:1-27. doi: 10.1007/s00289-022-04579-3.

DOI:10.1007/s00289-022-04579-3
PMID:36466080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9685138/
Abstract

In 2020, Coronavirus disease (COVID-19), a new viral respiratory disease caused by a virus that belongs to family, has been identified. It is a very severe flu that negatively affects the functions of the lung and other respiratory organs. COVID-19 virus can be transmitted between people either by touching an infected person or by direct contact with their respiratory droplets. Therefore, the COVID-19 virus has become a global concern due to its rapid spread and severity. Based on the World Health Organization report from 2 March 2020 to 24 October 2022, the total infected cases and deaths in Morocco are around 1,265,389 (3.46%) and 16,280 (0.04%), respectively. Recently, some scientists have found that chitosan, a polymer existed in nature, can inhibit COVID-19 infection and repair damaged tissue. Therefore, understanding chitosan mechanisms in controlling COVID-19, might lead to innovative strategies in the medical field, such as developing drugs against SARS-CoV-2, and replacing vaccines, which have negative side effects. This review aims to show the evolution of the COVID-19 pandemic worldwide, specifically in Morocco, its pathophysiology, and its ability to silence the immune system. This review also provides an overview of the treatments and measures applied to protect human beings and how chitosan acts and controls COVID-19.

摘要

2020年,人们发现了一种新型病毒性呼吸道疾病——冠状病毒病(COVID-19),它由一种属于冠状病毒科的病毒引起。这是一种非常严重的流感,会对肺部和其他呼吸器官的功能产生负面影响。COVID-19病毒可通过接触感染者或直接接触其呼吸道飞沫在人与人之间传播。因此,COVID-19病毒因其快速传播和严重性已成为全球关注的问题。根据世界卫生组织2020年3月2日至2022年10月24日的报告,摩洛哥的总感染病例和死亡人数分别约为1265389例(3.46%)和16280例(0.04%)。最近,一些科学家发现,壳聚糖这种天然存在的聚合物可以抑制COVID-19感染并修复受损组织。因此,了解壳聚糖控制COVID-19的机制,可能会带来医学领域的创新策略,比如研发抗SARS-CoV-2的药物,以及替代有副作用的疫苗。本综述旨在展示COVID-19大流行在全球范围内,特别是在摩洛哥的演变情况、其病理生理学以及它使免疫系统沉默的能力。本综述还概述了为保护人类而采取的治疗方法和措施,以及壳聚糖如何作用和控制COVID-19。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/1c6a64429226/289_2022_4579_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/e9adb460016d/289_2022_4579_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/def1d4b5e592/289_2022_4579_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/893dfd48e0c1/289_2022_4579_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/35ba55f3e841/289_2022_4579_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/42a9e9bf978f/289_2022_4579_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/1d9b242c188a/289_2022_4579_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/fd734b1cbb4d/289_2022_4579_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/1c6a64429226/289_2022_4579_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/e9adb460016d/289_2022_4579_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/def1d4b5e592/289_2022_4579_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/893dfd48e0c1/289_2022_4579_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/35ba55f3e841/289_2022_4579_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/42a9e9bf978f/289_2022_4579_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/1d9b242c188a/289_2022_4579_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/fd734b1cbb4d/289_2022_4579_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/940e/9685138/1c6a64429226/289_2022_4579_Fig8_HTML.jpg

相似文献

1
The evolution of the global COVID-19 epidemic in Morocco and understanding the different therapeutic approaches of chitosan in the control of the pandemic.摩洛哥全球新冠疫情的演变以及了解壳聚糖在控制疫情中的不同治疗方法。
Polym Bull (Berl). 2022 Nov 21:1-27. doi: 10.1007/s00289-022-04579-3.
2
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)针对轻度至中度症状的高危冠状病毒(COVID-19)患者的单克隆抗体疗法(存档)
3
Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.从分子机制和免疫反应角度治疗新冠肺炎的当前方法。
Saudi Pharm J. 2020 Nov;28(11):1333-1352. doi: 10.1016/j.jsps.2020.08.024. Epub 2020 Sep 1.
4
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗:当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
5
Current Strategies of Antiviral Drug Discovery for COVID-19.新型冠状病毒肺炎抗病毒药物研发的当前策略
Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.
6
Physical interventions to interrupt or reduce the spread of respiratory viruses.中断或减少呼吸道病毒传播的物理干预措施。
Cochrane Database Syst Rev. 2020 Nov 20;11(11):CD006207. doi: 10.1002/14651858.CD006207.pub5.
7
Evaluating And Referring Patients For Outpatient Monoclonal Antibody Therapy For Coronavirus In The Emergency Department (Archived)在急诊科评估并转诊患者接受冠状病毒门诊单克隆抗体治疗(存档)
8
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
9
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.工作场所干预措施以降低医疗机构外 SARS-CoV-2 感染的风险。
Cochrane Database Syst Rev. 2024 Apr 10;4(4):CD015112. doi: 10.1002/14651858.CD015112.pub3.
10
Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review.了解严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的分子生物学与冠状病毒病(COVID-19)大流行:综述
Infect Drug Resist. 2021 Jun 16;14:2259-2268. doi: 10.2147/IDR.S306441. eCollection 2021.

引用本文的文献

1
Coinfection with SARS-CoV-2 among patients with Streptococcus pneumoniae in Casablanca.卡萨布兰卡肺炎链球菌患者中合并感染新冠病毒的情况。
BMC Infect Dis. 2025 May 26;25(1):755. doi: 10.1186/s12879-025-10953-z.
2
Next-Generation Water Treatment: Exploring the Potential of Biopolymer-Based Nanocomposites in Adsorption and Membrane Filtration.下一代水处理:探索基于生物聚合物的纳米复合材料在吸附和膜过滤方面的潜力。
Polymers (Basel). 2023 Aug 16;15(16):3421. doi: 10.3390/polym15163421.
3
Chitosan-Based Particulate Carriers: Structure, Production and Corresponding Controlled Release.

本文引用的文献

1
Trend of Polymer Research Related to COVID-19 Pandemic: Bibliometric Analysis.与新冠疫情相关的聚合物研究趋势:文献计量分析
Polymers (Basel). 2022 Aug 12;14(16):3297. doi: 10.3390/polym14163297.
2
3D printed chitosan/polycaprolactone scaffold for lung tissue engineering: hope to be useful for COVID-19 studies.用于肺组织工程的3D打印壳聚糖/聚己内酯支架:有望对COVID-19研究有用。
RSC Adv. 2021 May 28;11(32):19508-19520. doi: 10.1039/d1ra03410c. eCollection 2021 May 27.
3
Review on Drug Regulatory Science Promoting COVID-19 Vaccine Development in China.
基于壳聚糖的微粒载体:结构、制备及相应的控释
Pharmaceutics. 2023 May 10;15(5):1455. doi: 10.3390/pharmaceutics15051455.
4
Natural Polymeric Composites Derived from Animals, Plants, and Microbes for Vaccine Delivery and Adjuvant Applications: A Review.源自动物、植物和微生物的天然高分子复合材料在疫苗递送和佐剂应用中的研究进展综述
Gels. 2023 Mar 15;9(3):227. doi: 10.3390/gels9030227.
关于药物监管科学推动中国新冠疫苗研发的综述
Engineering (Beijing). 2022 Mar;10:127-132. doi: 10.1016/j.eng.2022.01.001. Epub 2022 Jan 21.
4
Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.从风湿病学家的角度看抗风湿药物与新冠病毒肺炎
Pharmaceuticals (Basel). 2021 Dec 2;14(12):1256. doi: 10.3390/ph14121256.
5
COVID-19 vaccine guidelines was numerous in quantity but many lack transparent reporting of methodological practices.COVID-19 疫苗指南数量众多,但许多指南在方法实践的报告方面缺乏透明度。
J Clin Epidemiol. 2022 Apr;144:163-172. doi: 10.1016/j.jclinepi.2021.12.015. Epub 2021 Dec 14.
6
Epidemiological profile and performance of triage decision-making process of COVID-19 suspected cases in southern Tunisia.突尼斯南部新冠肺炎疑似病例的流行病学概况及分诊决策过程表现
Afr J Emerg Med. 2022 Mar;12(1):1-6. doi: 10.1016/j.afjem.2021.10.001. Epub 2021 Nov 4.
7
Innovations and development of Covid-19 vaccines: A patent review.Covid-19 疫苗的创新和发展:专利审查。
J Infect Public Health. 2022 Jan;15(1):123-131. doi: 10.1016/j.jiph.2021.10.021. Epub 2021 Oct 23.
8
China's COVID vaccines have been crucial - now immunity is waning.中国的新冠疫苗曾发挥关键作用——如今免疫力正在减弱。
Nature. 2021 Oct;598(7881):398-399. doi: 10.1038/d41586-021-02796-w.
9
SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray.使用一种具有黏膜黏附性和两亲性的壳聚糖抑制 SARS-CoV-2,这种壳聚糖可用作抗病毒鼻腔喷雾剂。
Sci Rep. 2021 Oct 8;11(1):20012. doi: 10.1038/s41598-021-99404-8.
10
Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco.在摩洛哥检测到的德尔塔变种(B.1.617.2)和卡帕变种(B.1.617.1)的基因组序列
Microbiol Resour Announc. 2021 Sep 30;10(39):e0072721. doi: 10.1128/MRA.00727-21.